Articles tagged with Parkinsons Disease
Researchers found that higher cerebrospinal fluid alpha-synuclein levels predict faster cognitive loss in Parkinson's disease, but not motor symptoms. The study, published in the American Journal of Pathology, offers new insights into PD pathology and potential management strategies.
Researchers at the University of Montreal have identified potential markers for dementia in Parkinson's disease patients with mild cognitive impairments. These markers include thinning in certain cortical areas and subcortical atrophy in grey matter, which may serve as a warning sign for developing dementia.
Researchers used ultra-high-field MRI to identify abnormalities in the substantia nigra, a key region affected by Parkinson's disease. The study showed promising results for early detection and classification of the condition, with high sensitivity and specificity rates.
Researchers are exploring the potential of RM-131, a ghrelin agonist, to treat constipation in Parkinson's patients. The study aims to improve bowel function and reduce symptoms such as abdominal pain and diarrhea.
Researchers at Université Laval discovered unusually high levels of the protein LINGO1 in people with essential tremor, which could lead to an effective treatment. The study found that inhibiting this protein may be a promising treatment avenue for essential tremor.
Researchers at NUS created a highly sensitive fluorescence probe to detect Monoamine Oxidase B (MAO-B) activity, which is elevated in patients with Parkinson's disease. The probe can monitor the progression of the disease and has potential as a biomarker.
A new study will explore the connection between dopamine, a 'feel-good' brain chemical, and hearing loss. The research aims to develop better therapies for people with communication disorders, including those with Parkinson's disease. The $1.6 million grant will fund a team led by Christine Portfors at Washington State University.
Researchers have developed a novel compound that protects mice against developing movement problems associated with Parkinson's disease. The compound, known as '12g', effectively prevented motor deficits linked to PD and showed promise as a potential new therapy.
Researchers aim to create personalized models for individual patients using their clinical data, enabling prediction of disease progress. The goal is to tailor treatment and improve healthcare outcomes for Parkinson's sufferers.
Researchers found that pesticides inhibiting aldehyde dehydrogenase enzyme increase Parkinson's disease risk, especially in people with ALDH2 gene variant. Exposure to multiple pesticides at work and home also increases risk.
A new study by UCLA researchers found that certain pesticides inhibit an enzyme called ALDH, which converts toxic aldehydes into less harmful agents, increasing the risk of Parkinson's disease. The study identified 11 pesticides that increase the risk, particularly in individuals with a common genetic variant of the ALDH2 gene.
Researchers at Max Planck Institute found that GDNF promotes the survival of mitochondria, preventing degeneration associated with a Parkinson's-related gene defect. This discovery could lead to more refined GDNF therapies for patients.
A new study suggests that a population of support cells called astrocytes could provide a promising approach to treat Parkinson's disease. Astrocytes, which are critical to maintaining a healthy environment in the brain, were found to repair multiple types of neurological damage caused by the disease.
Researchers at Duke University found that long-term spinal cord stimulation improved symptoms of Parkinson's-like disease in rats, protecting critical neurons and promoting better survival. The treatment may offer a new option for managing the condition.
A contest for the best particle tracking technique found that each method has its own strengths, but none were deemed unequivocally superior. The challenge, which aimed to track hundreds of intracellular organelles, was marked by oversimplification in image series, limiting algorithm performance on real data.
Researchers found that PINK1 and parkin are key to removing damaged mitochondria through a vesicular trafficking pathway. This early response helps protect against Parkinson's disease, which is linked to mitochondrial dysfunction. The study reveals a distinct quality control mechanism for mitochondria.
ProSavin, a novel gene therapy, has shown promise in reducing motor symptoms of Parkinson's disease by delivering dopamine-making genes directly into the brain. Significant improvements in motor scores were seen in all patients after treatment.
Researchers at the Gladstone Institutes found that mutant LRRK2 accumulation leads to cell death in Parkinson's neurons, and that alpha-synuclein plays a crucial role in this process. By understanding the interplay between these two proteins, scientists may develop new therapeutic strategies to target the disease's underlying mechanisms.
A study published in Neurology found disparities in the utilization of deep brain stimulation (DBS) treatment among Parkinson's patients, with those from lower socioeconomic backgrounds and minority-serving physicians facing significant barriers. DBS out-of-pocket costs are a contributing factor to these disparities.
A study published in JAMA Neurology found that inosine treatment increases blood and cerebrospinal fluid urate levels in early Parkinson disease patients, suggesting a potential strategy to slow disability progression. The treatment was also shown to be safe and tolerable, with minimal serious adverse events.
A Phase 2 trial found that inosine treatment successfully raised participants' urate levels without serious side effects. The study suggests that urate elevation may slow Parkinson disease progression and supports further investigation into its potential as a disease-modifying strategy.
Patients with Parkinson's disease struggle to recognize emotions in facial expressions and speech prosody. After surgery for deep brain stimulation, they show difficulty recognizing disgust and sadness, but this impairment is only temporary.
The Parkin enzyme activates a signal pathway that protects neurons from damage, increasing the expression of protective factors. This process may provide novel therapeutic targets to halt or delay neurodegeneration in Parkinson's disease.
The study involved 23 people with deep brain stimulators and 21 without stimulators, who completed driving tests in a simulator. Those with stimulators performed better on driving tests, especially when the device was turned on.
Scientists have identified a biological pathway linking Gaucher disease and Parkinson's disease. The connection is attributed to the accumulation of defective proteins, leading to an overload of cellular machines that dispose of defective proteins. This cascade triggers cell death in dopamine-producing cells, resulting in PD symptoms.
A new study shows that telemedicine consultations can effectively manage Parkinson's symptoms and improve quality of life. Virtual house calls enable individuals with the condition to live independently while receiving specialized care.
Researchers explore the connection between pesticides and Parkinson's disease, discovering two genetic mutations linked to increased risk in pesticide-exposed individuals. The study highlights the complexity of the disease and the need for further investigation into pesticide exposure and its potential effects on human health.
A review of subthalamic nucleus deep brain stimulation effects on Parkinson's disease patients reveals that while it improves motor features, social maladjustment and certain aspects of quality of life can be negatively impacted. Effective strategies are needed to mitigate these adverse effects and improve patients' overall well-being.
Researchers used RNA interference to identify dozens of genes that may regulate mitochondrial disposal, opening new drug targets for Parkinson's and related disorders. Four helper genes were found to enhance or inhibit tagging of damaged mitochondria.
Scientists at UCLA and Emory University have identified a biochemical signal in the blood associated with the faster-progressing form of Parkinson's. The researchers discovered that N8-acetyl spermidine is significantly elevated in rapid progressors, suggesting its potential as an early biomarker for the disease.
Researchers found that a volatile organic compound emitted by fungi, 1-octen-3-ol, attacks genes responsible for dopamine transport and packaging, leading to Parkinson's-like symptoms in fruit flies. The study suggests a potential link between fungal exposure and the degeneration of dopamine-producing neurons.
Researchers developed a simple dot test called the Triplets Learning Task (TLT) to assess dopamine loss in Parkinson's disease. The test shows promise as a non-invasive way to evaluate dopamine deficiency and may lead to new ways to improve treatment for PD patients.
A study published in Neural Regeneration Research found that Parkinson's patients with psychosis had greater white-matter fiber injury than those without psychosis. This difference may explain why psychosis often occurs in Parkinson's disease patients.
A new algorithm developed at Northwestern University can accurately track physical activity no matter where a patient carries their phone. The study's findings are crucial for improving the health of patients with Parkinson's disease, who may carry their phones in different locations throughout the day.
A study using voxel-based magnetic resonance morphometry found significant gray matter volume loss in Parkinson's disease patients compared to healthy controls. This loss was particularly pronounced in temporal, occipital, parietal, frontal, insular, and cerebellar regions.
A new drug, pimavanserin, has shown significant improvement in reducing psychotic symptoms in Parkinson's disease patients. The study found a 37% improvement in psychotic symptoms compared to placebo, with no worsening of motor symptoms reported.
A study led by TGen found that reduced SMG1 expression may contribute to alpha-synuclein pathology in Parkinson's disease and dementia. The researchers identified SMG1 as a regulator of alpha-synuclein aggregation, suggesting potential new therapeutic targets for treatment.
Researchers have identified a novel Parkinson's disease drug target and a compound capable of repairing neurons derived from human stem cells. Using a discovery platform combining yeast cells with human stem cells, scientists found that the compound reversed alpha-synuclein toxicity in yeast cells and partially rescued neurons in anima...
Researchers at University of Luxembourg's LCSB have published an interactive Parkinson's disease map, allowing scientists to systematically study the disease through a clearer understanding of existing knowledge. The map facilitates the identification of gaps in current understanding and establishes new research hypotheses.
NYSCF and PPMI collaborate to develop stem cell lines from patients, enabling researchers to study Parkinson's disease progression. The partnership aims to identify biomarkers and accelerate treatment development.
A study published in Neurology found that alpha-synuclein, a protein associated with Lewy bodies, is elevated in the skin of people with Parkinson's disease. This could lead to the development of a biomarker for early diagnosis and improved treatment options.
Researchers found significant cortical thinning and subcortical atrophy in Parkinson's patients with mild cognitive impairment, indicating faster neurodegeneration. This pattern may serve as a predictor of dementia in PD patients in the future.
A study published in Neurology found that people with depression are three times more likely to develop Parkinson's disease than those without depression. Researchers analyzed 4,634 individuals with depression and 18,544 without depression over a 10-year period.
A University of Houston researcher has won a $330,000 NSF grant to develop signal-processing techniques that interpret electrical activity recorded by deep brain stimulation probes. This technology aims to provide real-time feedback to neurosurgeons, allowing them to guide probe placement and perform surgeries faster and more accurately.
Researchers discovered a mechanism by which damaged mitochondria signal their own destruction, allowing cells to thrive. The 'eat me' signal involves cardiolipins and a protein called LC3, opening doors to potential research into cures for Parkinson's disease.
Scientists at University of Wisconsin-Madison discover that zinc ions play a crucial role in maintaining protein stability. A shortage of zinc can cause proteins to misfold and clump together, leading to cell death. Researchers identify a 'protein chaperone' called Tsa1 that prevents protein aggregation and maintains cellular balance.
Researchers have identified distinctive epigenetic modifications associated with Parkinson's disease that can be easily analyzed in blood samples. These changes replicate the epigenetic status of brain tissue cells, potentially simplifying early diagnosis of the disease.
Mayo Clinic researchers have discovered a genetic mutation that alters lipid metabolism in Parkinson's patients, leading to higher levels of ceramides and glucosylceramides in the blood. This biomarker is associated with severe cognitive impairment and dementia in Parkinson's disease.
A study of residents in Olmsted County, Minn., over 15 years found the incidence of dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) to be higher among older adults. The study also identified age-related increases in both DLB and PDD rates.
A study found a link between early-onset Parkinson's disease and a genetic deletion on chromosome 22, shedding light on molecular changes that lead to the disease. The deletion is associated with abnormal protein accumulations in the brain and may delay diagnosis by up to 10 years.
Researchers have taken detailed images and measurements of a brain protein thought to play a role in Parkinson's disease. The protein morphs from its globular shape into 'protofibril' strands that assemble into pore-like rings.
Scientists at the University of Sheffield have identified a synthetic drug, ursodeoxycholic acid (UDCA), that may slow down Parkinson's progression by making faulty mitochondria work normally again. This breakthrough discovery has the potential to improve symptoms and possibly halt disease progression.
Researchers at the University of Pennsylvania School of Medicine have developed a comprehensive test for protein biomarkers in spinal fluid that shows prognostic and diagnostic value in early stages of Parkinson's disease. The study found that patients with lower levels of tau and alpha synuclein had greater motor dysfunction, while th...
Researchers analyzed cerebrospinal fluid biomarkers in patients with early-stage Parkinson's disease (PD) and healthy controls. Lower levels of Alzheimer's beta-1-42 and tau proteins were found in PD patients, associated with motor severity. The study suggests that these biomarkers have prognostic potential for early-stage PD.
Researchers have identified a new biological target for combating Parkinson's disease by discovering a compound that eases symptoms in mice. The study found that a protein called AIMP2 activates a self-destruct pathway, leading to cell death, but also triggered the activation of PARP1 and PAR, which can be targeted by existing compounds.
Researchers at WashU Medicine found that corrupted proteins spread in the brain through a specific type of receptor called heparan sulfate proteoglycans (HSPGs). Blocking this receptor may aid treatment of Alzheimer's and Parkinson's diseases, potentially unifying understanding and treatment of multiple neurodegenerative conditions.
A UCSF team discovered that a chemical found in an anti-wrinkle cream can increase mutant PINK1 enzyme activity to near normal levels, reversing cell death caused by Parkinson's-disease mutations. This finding suggests potential for new treatment strategies and raises hope for combatting other diseases, including diabetes and cancer.
A study published in Nature Neuroscience reveals that genetic mutations linked to Parkinson's disease can cause problems with mitophagy, a process essential for eliminating damaged cells. The research suggests that targeting this pathway could lead to the development of more effective drug treatments.
A new study published in Neural Regeneration Research suggests that X-linked methyl-CpG binding protein 2 (MeCP2) may be a promising therapeutic target for treating Parkinson's disease. Researchers found that overexpressing MeCP2 in damaged human cells reduced apoptosis and increased tyrosine hydroxylase levels, indicating potential be...
Researchers analyzed data from over 30,000 patients to determine if Parkinson's disease and Alzheimer's disease share a common genetic risk factor. The study found no evidence of such overlap.